QS Investors LLC boosted its position in shares of Chemours Co (NYSE:CC) by 1.8% in the 4th quarter, Holdings Channel reports. The firm owned 140,595 shares of the specialty chemicals company’s stock after buying an additional 2,542 shares during the quarter. QS Investors LLC’s holdings in Chemours were worth $7,038,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Public Employees Retirement Association of Colorado raised its holdings in Chemours by 3.1% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 39,063 shares of the specialty chemicals company’s stock worth $1,955,000 after purchasing an additional 1,177 shares during the last quarter. Advisor Group Inc. increased its stake in shares of Chemours by 14.2% in the 4th quarter. Advisor Group Inc. now owns 10,425 shares of the specialty chemicals company’s stock valued at $523,000 after acquiring an additional 1,295 shares during the last quarter. Clearbridge LLC increased its stake in shares of Chemours by 93.6% in the 4th quarter. Clearbridge LLC now owns 2,689 shares of the specialty chemicals company’s stock valued at $135,000 after acquiring an additional 1,300 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Chemours by 6.4% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 22,514 shares of the specialty chemicals company’s stock valued at $1,127,000 after acquiring an additional 1,352 shares during the last quarter. Finally, Moors & Cabot Inc. increased its stake in shares of Chemours by 25.7% in the 4th quarter. Moors & Cabot Inc. now owns 7,169 shares of the specialty chemicals company’s stock valued at $363,000 after acquiring an additional 1,464 shares during the last quarter. 77.83% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Christian W. Siemer sold 15,088 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $47.37, for a total value of $714,718.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul Kirsch sold 13,770 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $50.01, for a total value of $688,637.70. Following the completion of the transaction, the insider now owns 63,093 shares of the company’s stock, valued at $3,155,280.93. The disclosure for this sale can be found here. Insiders sold a total of 58,239 shares of company stock valued at $2,848,608 over the last quarter. 1.14% of the stock is owned by insiders.
Chemours Co (CC) opened at $50.95 on Tuesday. The company has a debt-to-equity ratio of 4.74, a current ratio of 2.12 and a quick ratio of 1.55. Chemours Co has a 12-month low of $32.31 and a 12-month high of $58.08. The stock has a market capitalization of $9,137.16, a P/E ratio of 13.06, a P/E/G ratio of 0.61 and a beta of 3.03.
Chemours (NYSE:CC) last issued its quarterly earnings data on Wednesday, February 14th. The specialty chemicals company reported $1.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.24. Chemours had a return on equity of 115.54% and a net margin of 12.06%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same period in the previous year, the firm earned $0.08 EPS. Chemours’s quarterly revenue was up 19.1% compared to the same quarter last year. research analysts anticipate that Chemours Co will post 5.3 earnings per share for the current fiscal year.
Chemours declared that its board has authorized a share repurchase program on Friday, December 1st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the specialty chemicals company to buy shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
A number of analysts have recently commented on CC shares. Jefferies Group upped their price target on Chemours to $66.00 and gave the company a “buy” rating in a research note on Monday, December 4th. Goldman Sachs Group cut Chemours from a “buy” rating to a “neutral” rating and set a $55.00 price target for the company. in a research note on Wednesday, December 6th. Barclays reaffirmed a “buy” rating and issued a $60.00 price target on shares of Chemours in a research note on Wednesday, December 6th. Zacks Investment Research cut Chemours from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Morgan Stanley started coverage on Chemours in a research note on Tuesday, January 30th. They issued an “equal weight” rating and a $57.50 price target for the company. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Chemours has a consensus rating of “Buy” and a consensus target price of $57.95.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.